CD274 and hepatocellular carcinoma: At present, the best available first-line treatment for advanced HCC is a combination of PDL1 blockade with atezolizumab and VEGF blockade with bevacizumab (63).Combining PD-L1 glycosylation inhibitors with PD-1/PD-L1 blockade could further enhance T-cell activation and immune response (64).